Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Dexcom issues new recall for CGM apps due to safety risk—users urged to update immediately
The FDA has categorized this as a Class I recall. If patients update their phone or watch apps as needed, they can continue to use these devices like normal.
Why all heart patients should be vaccinated against the flu, COVID-19, RSV
The American College of Cardiology has shared new recommendations highlighting the protective benefits of a variety of vaccines. The new guidance also examines how to speak with patients who are hesitant to be vaccinated.
First study of its kind to focus on new therapy for hypoplastic left heart syndrome
The new trial represents a potential breakthrough in the treatment of one of the most devastating congenital heart defects.
Real-world data link semaglutide, tirzepatide to improved heart failure outcomes
GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.
Beta blockers ‘have no effect’ on heart attack patients
One researcher described the study's findings as "one of the most significant advances in heart attack treatment in decades.”

NOACs comparable to warfarin when treating AFib patients with valvular heart disease

Researchers examined the clinical impact of treating valvular AFib with dabigatran instead of warfarin.

Novavax NVX-CoV2373 COVID-19 vaccine myocarditis

FDA committee backs Novavax's COVID-19 vaccine despite heart damage concerns

The committee's approval comes days after the FDA shared details on a small number of trial participants who developed myocarditis or pericarditis after receiving the vaccine.

RAAS inhibitors lower risk of aneurysm rupture among patients with high blood pressure

Researchers also noted that uncontrolled hypertension, exposure to second-hand smoke and untreated type 2 diabetes were all associated with a greater rupture risk.

metformin chemodynamic therapy type 2 diabetes Nano Research

A new use for metformin? Popular type 2 diabetes medication may also improve cancer and infection therapies

Metformin appears to improve the impact of chemodynamic therapy, according to a new analysis in Nano Research.

Empagliflozin may reverse vascular aging, lower CVD risk

The SGLT2 inhibitor is already known as an effective medication for both type 2 diabetes and heart failure.

Anagrelide capsules FDA recall Teva Pharmaceuticals USA

FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes

The medication failed a routine dissolution test, meaning it could lose its effectiveness.

FDA posts guidance on managing risk of drug shortages

The Food & Drug Administration has drafted guidelines to help U.S. healthcare better prepare for and respond to events associated with these situations.

The FDFA has cleared tirzepatide (Mounjaro) from Eli Lilly for the treatment of diabetes.

FDA approves tirzepatide, Eli Lilly’s new type 2 diabetes drug, and the company shares an estimated price

The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.

Pharmaceutics

Dexcom issues new recall for CGM apps due to safety risk—users urged to update immediately

Why all heart patients should be vaccinated against the flu, COVID-19, RSV

First study of its kind to focus on new therapy for hypoplastic left heart syndrome

Real-world data link semaglutide, tirzepatide to improved heart failure outcomes

Beta blockers ‘have no effect’ on heart attack patients